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Health  outcomes  after  out  of hospital  cardiac  arrest  (OHCA)  are  extremely  poor,  with  only  7–9% of  patients
in the  United  Kingdom  (UK)  surviving  to hospital  discharge.  Currently  emergency  medical  services  (EMS)
use  either  tracheal  intubation  or newer  supraglottic  airway  devices  (SGAs)  to provide  advanced  airway
management  during  OHCA.  Equipoise  between  the  two  techniques  has led  to  calls  for  a  well-designed
randomised  controlled  trial.
The primary  objective  of the  AIRWAYS-2  trial  is to assess  whether  the  clinical  effectiveness  of  the  i-gel,
a  second-generation  SGA,  is  superior  to  tracheal  intubation  in the  initial  airway  management  of  OHCA
patients  in  the UK.  Paramedics  recruited  to  the AIRWAYS-2  trial are randomised  to use  either  tracheal
intubation  or  i-gel  as their  ﬁrst  advanced  airway  intervention.  Adults  who  have  had  a non-traumatic  OHCA
and are  attended  by an AIRWAYS-2  paramedic  are  retrospectively  assessed  against  eligibility  criteria  for
inclusion.The primary  outcome  is  the modiﬁed  Rankin  Scale  score  at hospital  discharge.  Secondary  objectives
are  to:  (i)  estimate  differences  between  groups  in outcome  measures  relating  to  airway  management,
hospital  stay  and  recovery  at 3 and  6  months;  (ii) estimate  the  cost  effectiveness  of the i-gel compared  to
tracheal  intubation.  Because  OHCA  patient  needs  immediate  treatment  there  are  several  unusual  features
and challenges  to  the  design  and  implementation  of  this  trial;  these  include  level of randomisation,  the
automatic  enrolment  model,  enrolment  of patients  that  lack  capacity  and  minimisation  of  bias.
Abbreviations: CAD, computer aided dispatch; CAG, Conﬁdentiality Advisory Group; CPR, cardiopulmonary resuscitation; CRF, case report form; CTEU, Clinical Trials and
valuation Unit; EEAST, East of England Ambulance Service NHS Trust; EMAS, East Midlands Ambulance Service NHS Trust; EMS, Emergency Medical Services; HES, Hospital
pisode  Statistics; ICC, intraclass correlation; ILCOR, International Liaison Committee on Resuscitation; JRCALC, Joint Royal Colleges Ambulance Liaison Committee; mRS,
odiﬁed Rankin Scale; NICE, National Institute for Health and Care Excellence; NHS, UK National Health Service; OHCA, out of hospital cardiac arrest; QALY, quality adjusted
ife  year; RCT, randomised controlled trial; ROSC, return of spontaneous circulation; SADE, serious adverse device event; SAE, serious adverse event; SGA, supraglottic airway;
WAST, South Western Ambulance Service NHS Foundation Trust; UK, United Kingdom; YAS, Yorkshire Ambulance Service NHS Trust.
 A  Spanish translated version of the abstract of this article appears as Appendix in the ﬁnal online version at http://dx.doi.org/10.1016/j.resuscitation.2016.09.016.
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Patient  enrolment  began  in June  2015.  The  trial will enrol  9070  patients  over  two  years.  The  results  are
expected  to  inﬂuence  future  resuscitation  guidelines.
Trial Registration  ISRCTN:  08256118.
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The United Kingdom (UK) has the highest reported incidence
f out of hospital cardiac arrest (OHCA) in Europe; 123 cases per
00,000 population per annum.1 Despite recent improvements,
urvival rates from cardiac arrest remain poor with approximately
–9% of patients in the UK surviving to hospital discharge, com-
ared with estimates of between 5% and 25% internationally.2–5
uring a cardiac arrest, the brain is exposed to a period of hypox-
emia and ischaemia, which may  result in death or cognitive
eﬁcits.6 Optimal cardiopulmonary resuscitation (CPR) and return
f spontaneous circulation (ROSC) are key factors associated with
voiding or minimising neurological impairment in the survivors of
HCA,9,10 and early effective airway management is fundamental
o this.
Traditional teaching suggests that tracheal intubation is the
est way to manage the airway during OHCA.11 However, this
ssumption has not been well tested,12 and pre-hospital intubation
ttempts by paramedics can be associated with complications such
s interruptions in chest compressions, unrecognised oesophageal
ntubation (particularly if waveform capnography is not available),
nd delays in accessing deﬁnitive care.13,14
Supraglottic airway devices (SGAs) are an alternative to intu-
ation. They are quicker and easier to place and may  avoid the
omplications of tracheal intubation.15 SGAs are used safely to
anage the airway during hospital procedures.16–18 They are also
n widespread use in UK National Health Service (NHS) emergency
edical services (EMS); in 2014/15 the London Ambulance Service
eported 1469/1775 (83%) successful OHCA intubations, com-
ared to 3149/3494 (90%) successful SGA placements.5 Equipoise
etween the two techniques has led to recent calls for a large ran-
omised controlled trial (RCT) of the two approaches.19,20
Between March 2012 and February 2013 we carried out a study
REVIVE-Airways) in a single NHS EMS  provider to assess the fea-
ibility of recruiting paramedics and patients to a study comparing
wo SGAs (i-gel and the Laryngeal Mask Airway Supreme) with
urrent practice (including tracheal intubation).21 REVIVE-airways
emonstrated that the study was feasible and informed the design
f AIRWAYS-2.
The Resuscitation Council (UK) 2015 guidelines state that the
ptimal airway technique for cardiac arrest is still unknown, and is
ikely to depend on the skills of the operator, the anticipated pre-
ospital time and patient-dependent factors.22 Evidence-based
nterventions to improve OHCA survival are still urgently required.
he AIRWAYS-2 trial has the potential to answer important
uestions about initial advanced airway management in OHCA,
xamining both survival rates and the quality of that survival.
ethods and analysis
ims and objectives
The aim of AIRWAYS-2 is to determine whether the i-gel (Inter-
urgical; Wokingham, UK), a second-generation SGA, is superior to
racheal intubation when used by an AIRWAYS-2 study paramedic
n non-traumatic OHCA in adults, in terms of both clinical and cost
ffectiveness.blished  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Speciﬁc objectives are to estimate:
1. The difference in the primary outcome of the modiﬁed Rankin
Scale (mRS) at hospital discharge (or 30 days post OHCA if the
patient is still in hospital) between groups of patients man-
aged with either the i-gel or tracheal intubation as their initial
advanced airway management strategy following OHCA.
2. Differences in secondary outcome measures relating to airway
management, hospital stay and recovery at 3 and 6 months
between groups of patients managed with either the i-gel or
tracheal intubation.
3. The cost effectiveness of the i-gel compared to tracheal intu-
bation, including estimation of major in-hospital resource use
(e.g. length of stay in intensive and high dependency care), and
associated costs in each group.
Design
AIRWAYS-2 is an open parallel two-group multi-centre clus-
ter RCT. The trial schema is shown in Fig. 1. Paramedics rather
than patients are randomised to one of the treatment groups and
all enrolled patients should be treated according to the enrolling
paramedic’s allocation.
Setting
The trial involves collaboration between four UK NHS EMS
providers (South Western Ambulance Service NHS Foundation
Trust (SWAST), East of England Ambulance Service NHS Trust
(EEAST), East Midlands Ambulance Service NHS Trust (EMAS), York-
shire Ambulance Service NHS Trust (YAS)) and the 95 NHS hospitals
served by the participating EMS  providers.
Paramedic population
Paramedics are eligible if they are employed by one of the four
participating EMS  providers, undertake general operational duties,
and can therefore be despatched to attend an OHCA as the ﬁrst or
second paramedic to arrive at the patient’s side. They must be regis-
tered with the Health and Care Professions Council and be qualiﬁed
to practice tracheal intubation in their current clinical role.
Randomisation
In AIRWAYS-2, paramedics working within SWAST, EMAS,
EEAST or YAS who consent to participate in the trial are randomly
allocated in a 1:1 ratio to one of the two  groups: i-gel or intubation
(i.e. each paramedic is a randomised cluster).
Randomisation is stratiﬁed by EMS  provider, years of paramedic
experience (greater than or equal to 5 years full-time operational
experience versus less than 5 years full-time operational expe-
rience) and urban/rural location of the base ambulance station
(deﬁned as greater than or equal to 5 miles versus less than 5
miles from the nearest hospital with an emergency department
that receives cardiac arrest patients).
Randomisation is performed using a secure computer system
developed by the Bristol Clinical Trials and Evaluation Unit (CTEU),
with allocation concealment that cannot be changed once allocated.
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he allocation is not revealed until sufﬁcient information to identify
he paramedic has been entered into the system. In order to avoid
ias caused by paramedics withdrawing from the study on the basis
f their allocation, paramedics are not randomised until half way
hrough a trial speciﬁc training session; prior to randomisation the
rial design and the need for individual equipoise is explained. If the
aramedic is willing to treat all OHCA patient they attend during
he study period by either intervention they give consent to take
art in the study. The paramedic is then randomised and completes
he training session with training that is speciﬁc to their allocation.
able 1
atient inclusion/exclusion criteria.
Inclusion criteria Exclus
Patient has had a non-traumatic cardiac arrest outside hospital Patien
18  years of age or older Resus
Royal 
Attended by a paramedic who is participating in the trial and is either
the  1st or 2nd paramedic to arrive at the patient’s side
Advan
partic
param
Resuscitation is commenced or continued by EMS  staff or respondera They a
Mouth
Patien
a A responder is someone acting for the ambulance service and dispatched by the am
ember  of the public who is trained by the ambulance service and volunteers.diagram.
Patient enrolment
Patient inclusion and exclusion criteria are described in
Table 1.
In order to prevent paramedics from being able to choose which
patients to enrol, this trial uses an automatic enrolment model; all
eligible patients attended by an AIRWAYS-2 paramedic for whom
resuscitation is attempted are included in the trial. A research
paramedic at each ambulance trust then carries out retrospective
checks against the study eligibility criteria.
ion criteria
t previously been recruited to the trial (determined retrospectively)
citation is considered inappropriate (based on guidelines produced by the Joint
Colleges Ambulance Liaison Committee; JRCALC)
ced airway management, inserted by another registered paramedic (not
ipating in AIRWAYS-2) doctor or nurse, is already in place when the AIRWAYS-2
edic arrives at patient’s side
re known to be already enrolled in another pre-hospital RCT
 opening <2 cm
t detained by Her Majesty’s Prison Service
bulance service to respond to emergency calls in their local area. They are often a
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The automatic enrolment model can give rise to situations
hich could lead to protocol deviations: (i) ineligible patients may
e consciously enrolled (these patients will be excluded from ﬁnal
nalysis), (ii) some eligible patients included in the ﬁnal population
ay not have been consciously enrolled by the attending AIRWAYS-
 paramedic and (iii) the wrong AIRWAYS-2 paramedic may  treat
he patient when two or more AIRWAYS-2 paramedics are present
n scene.
To ensure near-complete patient identiﬁcation we are using a
riangulation method developed during our feasibility study. Data
re collected on all OHCAs occurring within each EMS  provider from
hree separate sources:
. Direct paramedic report: participating paramedics are asked to
complete a case report form (CRF) immediately after each eligi-
ble OHCA that they attend, and notify the coordinating research
paramedic by telephone, text or e-mail.
. Daily review of the EMS  computer aided dispatch (CAD) system,
by a research paramedic, to identify all 999 calls identiﬁed as
suspected or conﬁrmed cardiac arrest, and follow-up with the
relevant staff to determine whether OHCA had occurred.
. Regular review of the OHCA data routinely collected by a par-
ticipating EMS  provider, and reported as part of the Ambulance
Service National Quality Indicator set in England.
atient consent
All enrolled patients who survive to hospital admission are
ollowed-up by a member of the research team. If a patient is likely
o survive to hospital discharge, the research staff consult with clin-
cal staff caring for the patient to (a) decide whether the survivor
as the mental capacity to provide consent, and (b) to determine
he optimal time to approach the patient and/or their family to seek
onsent/assent for further follow-up and data collection.
The patient or consultee can chose one of the following consent
ptions:
. Active follow-up: The patient will be actively followed up at dis-
charge, 3 and 6 months after the index OHCA. Quality of life and
mRS  score will be collected at these time points.
. Passive follow-up; routine data will be collected and the patient
will not be contacted again about the study.
The patient or consultee can also decline to take part in the
tudy. If this option is chosen no further data collection will take
lace.
In cases where consultee consent is obtained, patient capacity
ill be assessed at the 3 and 6 month follow-up. If the patient
egains capacity, consent to continue their involvement in the study
ill be sought from the patient.
rial interventions
racheal intubation (control group)
The current standard care pathway is tracheal intubation: the
lacement of a cuffed tube in the patient’s trachea to provide oxy-
en to the lungs and remove carbon dioxide. Tracheal intubation is
onsidered the “gold standard” of airway management, and is used
niversally in comatose survivors of cardiac arrest following their
dmission to hospital.
-gel (experimental group)
The intervention being studied is insertion of an i-gel, a second-
eneration SGA, as an alternative to tracheal intubation.n 109 (2016) 25–32
Aspects of airway management common to both groups
A standardised airway management algorithm was developed
by the 4 participating EMS  providers. Fig. 2a–d focuses on the initial
airway management attempts. Full details of the airway manage-
ment pathway are shown in Supplementary materials Figs. 1 and 2.
Care proceeds as normal for OHCA patients enrolled in the trial,
aside from the initial advanced airway management. All other inter-
ventions proceed according to standard resuscitation guidelines22
that are disseminated widely in the UK and internationally. Fol-
lowing ROSC sedation or neuromuscular blockade is not normally
provided prior to hospital arrival, and if an airway device is not
tolerated it will be removed. Patients who  die at the scene are man-
aged in accordance with nationally disseminated EMS  protocols.
Patients who  do not die at scene are transported to hospital and
treated using standard post-OHCA care pathways.
Due to the emergency nature of the trial we do expect devia-
tions from the AIRWAYS-2 treatment algorithm. True cross over
is deﬁned as the patient receiving the incorrect invention on the
ﬁrst advanced airway management attempt; other deviations can
occur during subsequent airway management attempts (see pro-
tocol deviations).
Outcome measures
Primary outcome
The primary outcome is the modiﬁed Rankin Scale (mRS) mea-
sured at hospital discharge (or 30 days after OHCA if the patient is
still in hospital). The mRS, which incorporates both quality of life
and survival, is widely used in OHCA research25,26 and comprises
a seven point scale (0 to 6) with lower scores representing bet-
ter recovery. Patients who die are given a score of six. The mRS  is
determined by a research nurse who  will assess the patient using a
simple ﬂow chart that has been used previously to assess patients
who have had a cardiac arrest.27 With prior permission of the
Health Research Authority Conﬁdentiality Advisory Group (CAG),
we are collecting survival data and mRS  at hospital discharge/30-
days for all enrolled patients, regardless of their consent status,
thereby ensuring close to 100% ascertainment of the primary
outcome.
Secondary outcomes
There are 12 secondary outcomes. These are listed in Table 2.
Sample size considerations
Patient sample size
In the REVIVE-Airways feasibility study, 9% of recruited patients
survived to hospital discharge.28,29 This is in-line with the current
rate of overall survival to discharge reported by English EMS.3 Using
survival as a proxy for mRS  score, a 2% improvement in the propor-
tion of patients achieving a good neurological outcome (deﬁned
as an mRS  score of 0–3), would be clinically signiﬁcant, and simi-
lar to the 2.4% difference in survival to discharge between tracheal
intubation and SGAs reported in a retrospective analysis.13
To identify a difference of 2% (8% vs. 10%, i.e. centred on 9%)
requires 4400 patients per group (at the 5% level for statistical sig-
niﬁcance and 90% power). However, each OHCA is not an indepen-
dent observation, as the patients are nested within a limited num-
ber of paramedics participating in the trial. Using data from our fea-
sibility study of 171 paramedics attending 597 OHCAs (3.6 patients
per paramedic per year), we  estimated the intraclass correlation
(ICC) to be <0.001. However, when estimating the sample size we
have assumed a conservative estimate for the ICC of 0.005. There-
fore we require a sample size of 9070 patients (4535 per group).
We powered the trial on mortality rather than mRS  because the
percentage of patients surviving with a good neurological outcome
J. Taylor et al. / Resuscitation 109 (2016) 25–32 29
Fig. 2. Airway management algorithm. (a) i-gel Airways-2 paramedic and at least one other person trained in CPR. (b) i-gel Solo Airways-2 Paramedic Response. (c) Intubation
Airways-2 paramedic and at least one other person trained in CPR. (d) Intubation Solo Airways-2 Paramedic Response.
Table 2
Outcome measures and data collection points.
Data item Out of hospital treatment
phase (data collection by
paramedics)
In  hospital/hospital
discharge (data collection
by hospital staff)
3 month post OHCA
(data collected by
research team)
6 month post OHCA
(data collected by
research team)
Primary and secondary outcomes
Initial ventilation success (visible chest rise)
√a
Regurgitation/aspiration
√a
Loss of a previously established airway
√a
Actual sequence of airway interventions delivered
√a
Return of spontaneous circulation
√a
Airway management in place when ROSC achieved
or  resuscitation discontinued
√a
Survival
√a √a √c √c
Modiﬁed Rankin Scale
√a √b √b
EQ-5D
√b √b √b
Resource use data
√a √c √c √c
Serious adverse events
√a √c √c √c
Length of hospital stay (captured separately for
different levels of care)
√c
Other data items
Eligibility
√a
Demography
√a √a
Approached for consent
√a
a Collected for all patients enrolled in trial (where patient survives to that point in the patient pathway).
b Only collected for patients that consent to active follow-up.
c Only collected for patients that consent to active or passive follow-up.
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annot be greater than the percentage of patients who survive. If
e had powered the trial for a 2% difference in mRS, we would not
ave had 90% power to detect the 2% difference in mortality, which
e acknowledge is a key secondary outcome.
aramedic sample size
In our feasibility study the mean number of patients enrolled
er participating paramedic was 3.6 per year. Therefore in order to
nrol the 9070 patients within the two year recruitment period we
stimate that we need to recruit at least 1300 paramedics. Across
he four EMS  providers participating in AIRWAYS-2, there are more
han 4300 eligible paramedics; we therefore need to enrol over 30%
f the paramedics employed by the four EMS  providers.
aramedic training
Standardised training materials have been developed to support
raining in research procedures and the allocated airway manage-
ent technique for both the intubation and i-gel groups. These
re administered to all participating paramedics before enrolment
ommences, with a research refresher halfway through the recruit-
ent period (at 12 months). Concerns have been raised that after
wo years using just one method of advanced airway management,
articipating paramedics risk becoming de-skilled in alternative
pproaches. Therefore, to support effective paramedic recruitment
nd retention, we will offer additional exit training to all partici-
ating paramedics to update their airway management skills once
atient enrolment has been completed.
The AIRWAYS-2 trial has been formally endorsed by the College
f Paramedics.
ata collection
For each eligible OHCA patient enrolled in the trial, the
aramedic who enrols the patient completes an airway manage-
ent CRF to capture baseline and secondary outcome data. If a
atient is admitted to hospital the consent and follow-up pro-
ess is coordinated by a regionally-based research nurse. Hospitals
rovide information on patient survival and recovery depending on
he consent option chosen by the patient/consultee.
The data collection schedule is summarised in Table 2.
atient follow-up
Follow-up occurs at 3 and 6 months (±4 weeks) after OHCA.
atients are asked to complete the level of function survey (mRS-
Q), the EQ5D-5L questionnaire, and a bespoke resource use
uestionnaire that captures information about (i) any equipment
r aids the patient requires, (ii) any stays away from home for
edical reasons and (iii) information on any contact with health
are professionals. Follow-up is carried out by telephone or post,
o-ordinated by the central CTEU team.
erious adverse event management
Serious adverse events (SAEs) and serious adverse device events
SADEs) are reported in accordance with the sponsor’s research-
elated adverse event reporting policy.
All trial patients are in an immediately life-threatening situa-
ion, most do not survive, and all survivors are hospitalised. SAEs
nd SADEs are only reported if they are potentially related to trial
articipation and they are unexpected (i.e. the event is not an
xpected occurrence for patients who have had a cardiac arrest).n 109 (2016) 25–32
End of the trial
For patients who  consent to follow-up, their participation ends
after the ﬁnal follow-up, six months after the index cardiac arrest.
For patients who do not consent to follow-up, their participation
ends immediately after approach for consent. The trial will end once
all participants have completed the follow-up phase.
Data analysis
The primary analysis will take place when follow-up is complete
for all recruited participants. A formal interim analysis is planned
at the mid-point of recruitment. The trial will continue as planned
unless the Data Monitoring and Safety Committee recommends
termination.
The primary outcome of mRS  at discharge or 30 days post OHCA
will be dichotomised into good recovery (0–3) versus poor recov-
ery/death (4–6), in line with previous reports. The mRS and other
binary outcomes will be analysed using multilevel mixed effects
logistic regression models, accounting for the clustering of data
within paramedics. Survival to 6 months and other time-to-event
outcomes will be analysed using survival analysis methods, again
allowing for clustering of patients by paramedic. Overall quality of
life utility scores and patient survival will be considered jointly to
assess whether the use of the i-gel simultaneously improves the
patient’s quality of life and reduces the risk of death.
Analyses will be performed according to the principle
of intention-to-treat, and reported according to CONSORT
guidelines.30,31 Two sub-group analyses are planned: the Utstein
comparator group (deﬁned as an arrest of a presumed cardiac cause
that was  bystander witnessed with an initial rhythm of ventricular
ﬁbrillation or pulseless ventricular tachycardia; estimated to make
up about 20% of the total) versus non-comparator group, and arrest
witnessed by EMS  staff (estimated to make up 6% of the total) versus
not witnessed by EMS  staff.
Protocol deviations
Most AIRWAYS-2 paramedics attend one to three eligible
patients per year and therefore some protocol deviations are
expected (see Supplementary material). To try to reduce deviations
as much as possible, monthly monitoring is carried out; research
paramedics are required to follow-up protocol deviations with the
relevant AIRWAYS-2 paramedic and reiterate the correct proce-
dures. We believe that ≥80% adherence to the AIRWAYS-2 protocol
is necessary to maintain the integrity of the study, with <10% “true
cross over” (incorrect intervention attempted ﬁrst).
Economic evaluation
An economic evaluation is being undertaken as part of
AIRWAYS-2 to estimate the cost effectiveness of the i-gel compared
to intubation, in accordance with recognised National Institute for
Health and Care Excellence (NICE) guidelines.32 This will help to
determine which type of airway management represents the best
use of NHS resources in this context.
Planned dissemination
A strategy has been implemented that includes dissemination
of the trial outputs to EMS  providers in the UK and overseas, to NHS
hospitals and through a publicly accessible website. Findings will
be published in high-impact journals, presented at conferences, cir-
culated in newsletters and will also be shared with international
groups responsible for the development of resuscitation guidelines.
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esearch approvals
Research ethics approval was granted by the Oxford C-South
entral Research Ethics Committee (reference 14/SC/1219) in
eptember 2014 and the Conﬁdentiality Advisory Group gave
pproval for the trial under Regulation 5 of the Health Service (Con-
rol of Patient Information) Regulations 2002 to process patient
dentiﬁable information without consent.
rial management
The Sponsor organisation is the South Western Ambulance Ser-
ices NHS Foundation Trust.
The contribution of the manufacturers of the i-gel is limited to
onﬁrming that the training of paramedics in the use of the devices
onforms to their recommended guidelines. The manufacturer has
o role in supplying devices or the design, conduct, analysis or
eporting of the trial.
The trial is over seen by a Trial Steering Committee and Data
onitoring and Safety Committee.
A patient and public research advisory group consisting of 10
embers meets every 4–6 months. The advisory group are involved
n debating various challenges regarding patient involvement; their
eedback has helped informed the design of the study.
iscussion
Due to OHCA being an extreme medical emergency requir-
ng immediate attendance and action by skilled clinical staff in a
ide range of unpredictable environments, the implementation
nd design of the AIRWAYS-2 trial has presented several challenges
elating to both ethical considerations around patient consent and
he potential for bias.
As AIRWAYS-2 involves the recruitment of incapacitated adults
nd there is no opportunity to obtain informed consent prior to
reatment, we use a deferred consent model for survivors and
aiver of consent for those who do not survive to discharge from
ntensive/coronary care. Following consultation with our patient
nd public advisory group we made the decision not to inform
he relatives of enrolled patients who do not survive the initial
ardiac arrest that they were involved in research; this applies to
he majority of patients enrolled, and is a model that was  adopted
uccessfully in our feasibility study. Informing relatives that their
ecently deceased loved one was involved in research has a high
isk of increasing distress and uncertainty without beneﬁt. We
elieve that this approach represents the best way  of answering
his important clinical question, and that the trial is justiﬁed by
oth its relevance to future healthcare and the degree of clinical
quipoise that currently exists, since both tracheal intubation and
he i-gel are already used routinely in English EMS  providers, and
nformation on the advanced airway management strategies used
uring resuscitation is not routinely provided to the relatives of
atients who do not survive OHCA.
To minimise bias we are using a combination of methods to iden-
ify all eligible patients, and an objective primary outcome measure
mRS) that with the permission of the CAG, can be obtained for all
urviving patients regardless of their consent status.
Ideally a trial would randomise at the level of the patient. How-
ver, due to the emergency situation this is not practicable in
IRWAYS-2. The procedures that would be required to achieve
andomisation of an eligible patient (contacting a remote server
r telephone line, or even opening a sealed opaque envelope) are
mpracticable at the point when an eligible patient is identiﬁed.
ne could argue that it would be possible to randomise at patient
evel on the way to an arrest but patient level randomisation before
atient eligibility is assessed would lead to many ineligible patientsn 109 (2016) 25–32 31
being randomised. Almost all similar research studies have been
cluster-randomised, often at the level of ambulance stations,33–35
which has also led to challenges relating to adherence with the allo-
cated interventions and bias. On the basis of the REVIVE-Airways
feasibility study,28,29 we chose to randomise paramedics, which
is advantageous because it more closely approaches individual
patient randomisation (i.e. more clusters and fewer participants
per cluster).
One of the key challenges faced whilst designing the AIRWAYS-2
study was  ensuring that there was a robust model of patient enrol-
ment. The automatic patient enrolment model used in this study
has the advantage of ensuring that all eligible patients are identiﬁed
and included in the study population. This signiﬁcantly reduces the
ability of AIRWAYS-2 paramedics to introduce selection bias.
The use of an automatic enrolment model could however
increase the likelihood of protocol deviations, including non-
adherence to the airway management algorithm. The automatic
enrolment model will also have some limitations that may affect
the quality of the data; if a patient is included in the study that
the AIRWAYS-2 paramedic did not consciously enrol this may  lead
to missing airway management data or poor quality data if an
AIRWAYS-2 paramedic is asked to retrospectively recall the details
of an event.
The results from the AIRWAYS-2 trial, together with results from
the PART trial (a similar North American study),36 have the poten-
tial to answer important questions about initial advanced airway
management in OHCA. It is hoped that ﬁndings from these trials
will help to reduce premature mortality, enhance quality of life
and reduce the use of health and social care resources by leading
to important changes in the treatment protocols recommended by
the International Liaison Committee on Resuscitation (ILCOR).
Trial status
The ﬁrst paramedic was  randomised in March 2015. The trial
opened to patient enrolment in three EMS providers in June 2015
and the other EMS  provider in July 2015. Paramedic and patient
recruitment is on-going.
The full protocol is available from www.nets.nihr.ac.uk/
projects/hta/12167102.
Independent Trial Steering Committee members
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